Xavier Montalban


Scientist, Li Ka Shing Knowledge Institute

Research Programs


Dr. Xavier Montalban is an internationally recognized neurologist who is considered a key opinion leader within the field of multiple sclerosis (MS). Dr. Montalban has held diverse leadership positions and is currently a Professor of Medicine and Director of the Neurology Department at the University of Toronto. He also serves as Chair of the Department of Neurology-Neuroimmunology and Director of the Multiple Sclerosis Centre of Catalonia at the Vall d’Hebron University Hospital in Barcelona, Spain. The Multiple Sclerosis Centre of Catalonia, or Cemcat, is accredited as a national flagship service for the MS care process within the context of the Flagship Centres, Units, and Services programme of the Spanish Ministry of Health. Dr. Montalban is a former president of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and recently co-directed the development of the first Multiple Sclerosis Treatment Guidelines for ECTRIMS and the European Academy of Neurology. He has contributed more than 500 publications and several book chapters to the academic arena, served on multiple steering committees of clinical trials related to multiple sclerosis, and is a valued member of the International Panel on Multiple Sclerosis Diagnostic Criteria and Clinical Trials. With more than 25 years of research, Dr. Montalban continues to strive to discover more effective therapies for patients with MS and has brought paradigm shifts to the way we understand and treat MS.

Recent Publications

  1. Balk, LJ, Coric, D, Knier, B, Zimmermann, HG, Behbehani, R, Alroughani, R et al.. Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. Mult Scler J Exp Transl Clin. ;5 (3):2055217319871582. doi: 10.1177/2055217319871582. PubMed PMID:31523449 PubMed Central PMC6728683.
  2. Cohen, JA, Comi, G, Selmaj, KW, Bar-Or, A, Arnold, DL, Steinman, L et al.. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019; :. doi: 10.1016/S1474-4422(19)30238-8. PubMed PMID:31492652 .
  3. Comi, G, Kappos, L, Selmaj, KW, Bar-Or, A, Arnold, DL, Steinman, L et al.. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019; :. doi: 10.1016/S1474-4422(19)30239-X. PubMed PMID:31492651 .
  4. Midaglia, L, Mulero, P, Montalban, X, Graves, J, Hauser, SL, Julian, L et al.. Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. J. Med. Internet Res. 2019;21 (8):e14863. doi: 10.2196/14863. PubMed PMID:31471961 .
  5. Sinnecker, T, Clarke, MA, Meier, D, Enzinger, C, Calabrese, M, De Stefano, N et al.. Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurol. 2019; :. doi: 10.1001/jamaneurol.2019.2478. PubMed PMID:31424490 PubMed Central PMC6704746.
  6. Cadavid, D, Mellion, M, Hupperts, R, Edwards, KR, Calabresi, PA, Drulović, J et al.. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18 (9):845-856. doi: 10.1016/S1474-4422(19)30137-1. PubMed PMID:31285147 .
  7. Saposnik, G, Mamdani, M, Montalban, X, Terzaghi, M, Silva, B, Saladino, ML et al.. Traffic Lights Intervention Reduces Therapeutic Inertia: A Randomized Controlled Trial in Multiple Sclerosis Care. MDM Policy Pract. ;4 (1):2381468319855642. doi: 10.1177/2381468319855642. PubMed PMID:31259250 PubMed Central PMC6589979.
  8. International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu, International Multiple Sclerosis Genetics Consortium. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell. 2019;178 (1):262. doi: 10.1016/j.cell.2019.06.016. PubMed PMID:31251915 PubMed Central PMC6602362.
  9. Peroni, S, Sorosina, M, Malhotra, S, Clarelli, F, Osiceanu, AM, Ferrè, L et al.. A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis. Mult. Scler. 2019; :1352458519851428. doi: 10.1177/1352458519851428. PubMed PMID:31221001 .
  10. Arrambide, G, Tintore, M, Montalban, X. Oligoclonal bands do not represent dissemination in time in the 2017 revisions to the McDonald criteria. Mult. Scler. 2019; :1352458519846103. doi: 10.1177/1352458519846103. PubMed PMID:31094275 .
Search PubMed

Affiliations & Other Activities

  • The Waugh Family Chair in Multiple Sclerosis Research, St. Michael’s Hospital
  • Medical Director, the BARLO MS Centre, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
  • Division Director, Department of Neurology, University of Toronto
  • Director, Centre d’Esclerosi Múltiple de Catalunya (Cemcat)